Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO5083945 versus cetuximab pharmacodynamic study in operable head and neck squamous cell carcinoma
NL-OMON34195Withdrawn
- Sponsor
- Roche
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of imgatuzumab and cetuximab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Roche. Primary endpoints: Immune cell infiltration and Immune cell activation. Planned start Oct 2010; status: withdrawn.
02
Drugs
imgatuzumabcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON34195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34195.